UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The chemical class of quinazoline compounds provides a core structure for the design of anticytomegaloviral kinase inhibitors

Antiviral research, 2016-10, Vol.134, p.130-143

2016

Volltextzugriff (PDF)

CDK9 inhibition as an effective therapy for small cell lung cancer

Cell death & disease, 2024-05, Vol.15 (5), p.345-345, Article 345

2024

Volltextzugriff (PDF)

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties

British journal of pharmacology, 2009-10, Vol.158 (4), p.1153-1164

2009

Volltextzugriff (PDF)

Novel members of quinoline compound family enhance insulin secretion in RIN-5AH beta cells and in rat pancreatic islet microtissue

Scientific reports, 2017-03, Vol.7 (1), p.44073, Article 44073

2017

Volltextzugriff (PDF)

791: Investigation of the mode of action of sunitinib kinase inhibitor profile analogues in insulin release

European journal of cancer (1990), 2014-07, Vol.50, p.S190-S191

2014

Volltextzugriff (PDF)

Novel, selective CDK9 inhibitors for the treatment of HIV infection

Current medicinal chemistry, 2011, Vol.18 (3), p.342-358

2011

Volltextzugriff (PDF)

Reliability of logP predictions based on calculated molecular descriptors: a critical review

Current medicinal chemistry, 2002-10, Vol.9 (20), p.1819-1829

2002

Volltextzugriff (PDF)

Pro-Apoptotic and Anti-Apoptotic Molecules Affecting Pathways of Signal Transduction

Annals of the New York Academy of Sciences, 2003-12, Vol.1010 (1), p.109-112

2003

Volltextzugriff (PDF)

Pharmacophore and binding analysis of known and novel B-RAF kinase inhibitors

Current medicinal chemistry, 2014-06, Vol.21 (17), p.1938-1955

2014

Volltextzugriff (PDF)

Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing

Current medicinal chemistry, 2013-04, Vol.20 (10), p.1203-1217

2013

Volltextzugriff (PDF)

Characterization of binding mode of imatinib to human α1-acid glycoprotein

International journal of biological macromolecules, 2012-04, Vol.50 (3), p.788-795

2012

Volltextzugriff (PDF)

801: Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors − suggestion of combination therapy

European journal of cancer (1990), 2014-07, Vol.50, p.S193-S194

2014

Volltextzugriff (PDF)

Signalling inhibitors against Mycobacterium tuberculosis--early days of a new therapeutic concept in tuberculosis

Current medicinal chemistry, 2008-11, Vol.15 (26), p.2760-2770

2008

Volltextzugriff (PDF)

Structure -activity relationships of PDE5 inhibitors

Current medicinal chemistry, 2008-07, Vol.15 (16), p.1570-1585

2008

Volltextzugriff (PDF)

Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma

Current cancer drug targets, 2010-05, Vol.10 (3), p.332-342

2010

Volltextzugriff (PDF)

Acid−Base Profiling of Imatinib (Gleevec) and Its Fragments

Journal of medicinal chemistry, 2005-01, Vol.48 (1), p.249-255

2005

Volltextzugriff (PDF)

Prediction oriented QSAR modelling of EGFR inhibition

Current medicinal chemistry, 2006-02, Vol.13 (3), p.277-287

2006

Volltextzugriff (PDF)

Protein Kinase C ζ Drives Sphingomyelin Metabolism in the Nucleus During Cell Proliferation

Current chemical biology, 2013-10, Vol.7 (2), p.131-138

2013

Volltextzugriff (PDF)

TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers

Molecular oncology, 2014-05, Vol.8 (3), p.508-519

2014

Volltextzugriff (PDF)

Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling

Cancer research (Chicago, Ill.), 2005-08, Vol.65 (15), p.6919-6926

2005

Volltextzugriff (PDF)

Machine learning and docking models for Mycobacterium tuberculosis topoisomerase I

Tuberculosis (Edinburgh, Scotland), 2017-03, Vol.103, p.52-60

2017

Volltextzugriff (PDF)

High-Affinity Interaction of Tyrosine Kinase Inhibitors with the ABCG2 Multidrug Transporter

Molecular pharmacology, 2004-06, Vol.65 (6), p.1485-1495

2004

Volltextzugriff (PDF)

Selectivity profiling and off-target identification of clinically relevant kinase inhibitors for gastrointestinal tumors

Zeitschrift für Gastroenterologie, 2008, Vol.46 (5)

2008

Volltextzugriff (PDF)

PDGFR TK assay for screening inhibitory compound-libararies

Zeitschrift für Gastroenterologie, 2004-05, Vol.42 (5)

2004

Volltextzugriff (PDF)

Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells

International journal of nanomedicine, 2012-01, Vol.7 (default), p.417-433

2012

Volltextzugriff (PDF)

1 – 25 von 91

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(57)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

The chemical class of quinazoline compounds provides a core structure for the design of anticytomegaloviral kinase inhibitors

CDK9 inhibition as an effective therapy for small cell lung cancer

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties

Novel members of quinoline compound family enhance insulin secretion in RIN-5AH beta cells and in rat pancreatic islet microtissue

791: Investigation of the mode of action of sunitinib kinase inhibitor profile analogues in insulin release

Novel, selective CDK9 inhibitors for the treatment of HIV infection

Reliability of logP predictions based on calculated molecular descriptors: a critical review

Pro-Apoptotic and Anti-Apoptotic Molecules Affecting Pathways of Signal Transduction

Pharmacophore and binding analysis of known and novel B-RAF kinase inhibitors

Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing

Characterization of binding mode of imatinib to human α1-acid glycoprotein

801: Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors − suggestion of combination therapy

Signalling inhibitors against Mycobacterium tuberculosis--early days of a new therapeutic concept in tuberculosis

Structure -activity relationships of PDE5 inhibitors

Inhibition of c-Met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma

Acid−Base Profiling of Imatinib (Gleevec) and Its Fragments

Prediction oriented QSAR modelling of EGFR inhibition

Protein Kinase C ζ Drives Sphingomyelin Metabolism in the Nucleus During Cell Proliferation

TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers

Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling

Machine learning and docking models for Mycobacterium tuberculosis topoisomerase I

High-Affinity Interaction of Tyrosine Kinase Inhibitors with the ABCG2 Multidrug Transporter

Selectivity profiling and off-target identification of clinically relevant kinase inhibitors for gastrointestinal tumors

PDGFR TK assay for screening inhibitory compound-libararies

Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells

Suchergebnisse filtern